Allergy Therapeutics plc

AGY

GB00B02LCQ05

Biotechnology & Medical Research

Delayed London S.E. Other stock markets 05:01:06 2024-05-21 am EDT			5-day change	1st Jan Change
3.44 ^GBX	+1.18%		+9.21%	+37.60%

May. 07	Abingdon Health buys IVDeology Holdings	AN
May. 07	Allergy Therapeutics plc Provides Further Details from Positive Top Line Results from G306 Phase III Field Study G306 to Evaluate the Efficacy and Safety of Grass MATA MPL	CI

Rights Issue: 6 new shares @ 0.01 GBP for 1 existing share

September 27, 2023

Latest news about Allergy Therapeutics plc

Abingdon Health buys IVDeology Holdings	May. 07	AN
Allergy Therapeutics plc Provides Further Details from Positive Top Line Results from G306 Phase III Field Study G306 to Evaluate the Efficacy and Safety of Grass MATA MPL	May. 07	CI
Allergy Therapeutics Announces Resignation of Mary Tavener as Non-Executive Director	Apr. 03	CI
EARNINGS AND TRADING: Solid State ups outlook; Quartix trading in line	Mar. 27	AN
Allergy Therapeutics Gets OK to Draw Down GBP15 Million From Amended Loan Facility	Mar. 27	MT
AIM WINNERS & LOSERS: Norman Broadbent profit swing on rising revenue	Mar. 27	AN
Earnings Flash (AGY.L) ALLERGY THERAPEUTICS Reports Fiscal H1 Revenue GBP33.6M	Mar. 27	MT
Earnings Flash (AGY.L) ALLERGY THERAPEUTICS Posts Fiscal H1 Loss GBX-0.58	Mar. 27	MT
Allergy Therapeutics plc Provides Sales Guidance for the Second Half and Full Year Ending on 30 June 2024	Mar. 27	CI
Allergy Therapeutics plc Reports Earnings Results for the Half Year Ended December 31, 2023	Mar. 27	CI
Allergy Therapeutics starts dosing patients in peanut allergy trial	Mar. 12	AN
Allergy Therapeutics Announces Commencement of Subcutaneous Dosing of Peanut Allergic Patients in the Phase I/IIa PROTECT Trial Evaluating its Novel Virus-Like Particle Based Peanut Allergy Vaccine Candidate	Mar. 12	CI
Allergy Therapeutics plc Announces Appointment of Shaun Furlong to Board of Directors	Mar. 11	CI
Allergy Therapeutics forecasts revenue drop but trials going well	Feb. 14	AN
Alliance Pharma appoints chair; FireAngel sales down	Feb. 05	AN
Scancell's Chief Development Officer to Step Down	Feb. 05	MT
Allergy Therapeutics resumes trading on AIM; annual revenue plunges	Jan. 30	AN
Allergy Therapeutics amends facility, plans warrant issue	Dec. 27	AN
Allergy Therapeutics Agrees Amendment to Loan Facility	Dec. 27	MT
EARNINGS AND TRADING: Redx full year revenue tumbles; loss widens	Dec. 15	AN
Allergy Therapeutics' Allergic Rhinoconjunctivitis Treatment Returns Positive Data in Late-stage Trial	Dec. 13	MT
Allergy Therapeutics shares jump as hails grass allergy jab data	Dec. 13	AN
AIM WINNERS & LOSERS: Impellam climbs on GBP483 million takeover offer	Dec. 13	AN
Allergy Therapeutics plc Provides an Update on the Data Analysis of Its Pivotal G306 Phase III Trial of Grass MATA MPL	Dec. 13	CI
Allergy Therapeutics in Advanced Talks for Potential Funding; Shares Drop	Dec. 11	MT

Chart Allergy Therapeutics plc

Duration

Period

More charts

Allergy Therapeutics plc is a United Kingdom-based integrated specialty pharmaceutical company. The Company is focused on the treatment and diagnosis of allergic disorders, including aluminum-free immunotherapy vaccines that have the potential to cure disease. The Company sells proprietary and third-party products from its subsidiaries in nine European countries and via distribution agreements in an additional ten countries. Its pipeline of products in clinical development includes vaccines for grass, tree and house dust mite, and peanut allergy vaccine in pre-clinical development. Its pipeline candidates include Grass MATA MPL, Birch MATA MPL, Ragweed MATA, Bee Venom SCIT, Wasp Venom SCIT, Ragweed MATA MPL, Trees MATA, Trees MATA MPL, Peanut SCIT and others. Its commercial portfolio of products includes Pollinex, Venomil and Acarovac. It operates in Austria, Germany, Italy, the Netherlands, Spain, Switzerland, and the United Kingdom.

Sector

Biotechnology & Medical Research

Calendar

2024-09-24 - Q4 2024 Earnings Release (Projected)

More about the company

	1st Jan change	Capi.
ALLERGY THERAPEUTICS PLC	+37.60%	206M
VERTEX PHARMACEUTICALS INCORPORATED	+9.58%	115B
REGENERON PHARMACEUTICALS, INC.	+12.41%	107B
ARGENX SE	-3.52%	21.6B
BIONTECH SE	-12.38%	22.31B
GENMAB A/S	-6.87%	19.19B
BEIGENE, LTD.	-3.35%	18.23B
WUXI APPTEC CO., LTD.	-38.57%	17.62B
NEUROCRINE BIOSCIENCES, INC.	+7.51%	14.26B
SAREPTA THERAPEUTICS, INC.	+35.67%	12.37B

Bio Therapeutic Drugs

Allergy Therapeutics plc

Equities

AGY

GB00B02LCQ05

Biotechnology & Medical Research

Rights Issue: 6 new shares @ 0.01 GBP for 1 existing share

Latest news about Allergy Therapeutics plc

Chart Allergy Therapeutics plc

Company Profile

Income Statement Evolution

Quarterly earnings - Rate of surprise

Sector Bio Therapeutic Drugs